evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

163 questions · 169 findings · 42 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 29 · 17.2%GRADE not reported 8 · 4.7%Very low 29 · 17.2%Low 45 · 26.6%Moderate 52 · 30.8%High 6 · 3.6%

Oral corticosteroids vs placebo or NSAID

Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis

Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).

2 findings from 1 review

Oral corticosteroids vs placebo or NSAID

Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis

Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).

1 finding from 1 review

Intramuscular corticosteroids vs oral corticosteroid

Relapse · patients with acute asthma

Intramuscular corticosteroids showed no clear difference in relapse compared with oral corticosteroids (low certainty).

3 findings from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Death at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids showed no clear difference in death at final compared with placebo/no treatment/steroids (low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

End‐stage renal disease · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to lower end‐stage kidney disease at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Total remission (complete or partial) at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to higher total remission (complete or partial) at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Complete remission · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids probably leads to higher complete remission at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Relapse · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes recurrence of disease (relapse) at final compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

100% increase in SCr at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids showed no clear difference in 100% increase in serum creatinine at final compared with placebo/no treatment/steroids (moderate certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome

Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events ‐ infection at 3 years · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ infection at 3 years compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Oral alkylating agents ± steroids vs steroids or placebo or both, or no treatment

Adverse events: malignancy · primary membranous nephropathy in adults with nephrotic syndrome

It is very uncertain whether oral alkylating agents ± steroids changes adverse events ‐ malignancy at final compared with placebo/no treatment/steroids (very low certainty).

1 finding from 1 review

Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3 weeks for 27 weeks) vs placebo injection

Mean number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care

Depot corticosteroids (systemic; 40 mg methylprednisolone IM every 3… showed no clear difference in mean number of oral ulcers compared with placebo (saline IM injection); GRADE not reported.

1 finding from 1 review